Quinupristin and dalfopristin are streptogramin antibiotics, which, like macrolides and lincosamides, inhibit the synthesis of bacterial proteins.
Quinupristin/dalfopristin (Q/D) is given together in a fixed 30/70 combination; this combination has synergistic bactericidal activity against the following:
-
Streptococci and staphylococci, including strains resistant to other antibiotic classes
-
Some gram-negative anaerobic bacilli
-
Peptostreptococcus species
-
Atypical respiratory pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila)
Q/D inhibits Enterococcus faecium, including vancomycin-resistant strains. Enterococcus faecalis is resistant.
Q/D is given via a central IV catheter because phlebitis frequently occurs when Q/D is given via a peripheral vein. Up to 30% of patients develop significant myalgias.
Dosage reduction is required for severe hepatic insufficiency but not for renal insufficiency.
Safety Warning
Drugs Mentioned In This Article
| Drug Name | Select Trade |
|---|---|
Quinupristin/dalfopristin |
SYNERCID |
vancomycin |
VANCOCIN |
